Drug-Induced Leukocytoclastic Vasculitis From an Unreported Source: Daptomycin
- PMID: 40385906
- PMCID: PMC12085776
- DOI: 10.7759/cureus.82490
Drug-Induced Leukocytoclastic Vasculitis From an Unreported Source: Daptomycin
Abstract
Leukocytoclastic vasculitis (LCV) is a rare small-vessel vasculitis caused by immune-complex-mediated deposition on endothelial cells of dermal capillaries. Common triggers include medications, infections, autoimmune disorders, and malignancies. We present a case of a 58-year-old male who developed daptomycin-induced LCV after being treated for Methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. The patient experienced painful palpable purpura on his lower extremities, which was diagnosed as LCV by skin biopsy. At the time of the biopsy, warfarin and daptomycin were discontinued, and the patient was transitioned to heparin and ceftaroline. MRSA-induced LCV was ruled out, due to negative blood cultures and adequate source control of his infection at the time of development of the skin lesions. Warfarin-induced skin necrosis (WISN) was ruled out based on histopathological findings. This case is clinically significant as it represents the first reported case of LCV associated with daptomycin use. It underscores the importance of considering the patient's history, clinical presentation, and histopathological findings to ensure prompt recognition and management of this rare drug reaction, allowing for the resolution of LCV.
Keywords: antibiotic adverse effects; cutaneous drug reaction; daptomycin adverse reaction; drug-induced vasculitis; histopathology of vasculitis; immune complex-mediated vasculitis; leukocytoclastic vasculitis (lcv); mrsa endocarditis; small vessel vasculitis.
Copyright © 2025, Priessnitz et al.
Conflict of interest statement
Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures





Similar articles
-
Vancomycin-Induced Leukocytoclastic Vasculitis: A Rare Complication From a Commonly Used Medication.Cureus. 2023 Mar 22;15(3):e36532. doi: 10.7759/cureus.36532. eCollection 2023 Mar. Cureus. 2023. PMID: 37102000 Free PMC article.
-
Oxacillin-induced leukocytoclastic vasculitis.IDCases. 2019 Apr 17;17:e00539. doi: 10.1016/j.idcr.2019.e00539. eCollection 2019. IDCases. 2019. PMID: 31384556 Free PMC article.
-
Leukocytoclastic vasculitis in association with linear epidermal basement membrane zone immunoglobulin deposition: Linear vasculitis.Clin Dermatol. 2022 Nov-Dec;40(6):639-650. doi: 10.1016/j.clindermatol.2022.07.011. Epub 2022 Jul 28. Clin Dermatol. 2022. PMID: 35907580
-
Diagnosis and management of leukocytoclastic vasculitis.Intern Emerg Med. 2021 Jun;16(4):831-841. doi: 10.1007/s11739-021-02688-x. Epub 2021 Mar 13. Intern Emerg Med. 2021. PMID: 33713282 Free PMC article. Review.
-
Management of leukocytoclastic vasculitis.J Dermatolog Treat. 2005;16(4):193-206. doi: 10.1080/09546630500277971. J Dermatolog Treat. 2005. PMID: 16249140 Review.
References
-
- Dermatologic aspects of systemic vasculitis. Younger DS, Carlson A. Neurol Clin. 2019;37:465–473. - PubMed
-
- Baigrie D, Crane JS. StatPearls. Treasure Island, FL: StatPearls Publishing; 2023. Leukocytoclastic vasculitis. - PubMed
-
- Coumarin-induced skin necrosis. Bauer KA. Arch Dermatol. 1993;129:766–768. - PubMed
Publication types
LinkOut - more resources
Full Text Sources